In a phase 1b open-label trial of 35 adults with chronic hepatitis B on stable nucleos(t)ide therapy, VRON-0200 immunotherapy was well tolerated with no treatment-related serious adverse events; 23 of 27 given it alone had HBsAg declines at day 360.
RCTn = 35
Gane et al. VRON-0200 alone and in combination with investigational antivirals for participants with chronic hepatitis B virus infection receiving stable nucleos(t)ide therapy: a phase 1b, randomised, open-label, multicentre trial